Wegovy (semaglutide) 0.5mg

Wegovy® (Semaglutide) 0.5 mg is a prescription medication containing semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist. Developed by Novo Nordisk, Wegovy is indicated for chronic weight management in adults and eligible adolescents with obesity or overweight, in combination with a reduced-calorie diet and increased physical activity, in accordance with approved local prescribing information.

The 0.5 mg strength is typically used following the initial 0.25 mg starting dose, allowing treatment to be gradually escalated under the supervision of a qualified healthcare provider.

Benefits

• GLP-1 receptor agonist
• Once-weekly subcutaneous administration
• Common dose following the initial 0.25 mg starting dose
• Supports long-term weight management when combined with diet and exercise
• Convenient carton containing 1 prefilled single-dose injection pen
• Manufactured to strict pharmaceutical quality standards

Common Clinical Use

• Chronic weight management
• Dose escalation following the 0.25 mg starting dose
• Physician-supervised obesity management

Product Specifications

Storage

Store refrigerated at 2°C–8°C. Do not freeze. Keep the pen in its original carton to protect it from light. Follow the manufacturer's recommendations regarding room-temperature storage before use.

Important Information

Prescription medicine.

Wegovy must be used only under the supervision of a qualified healthcare professional and in accordance with the approved prescribing information in your country. Read the accompanying patient information leaflet before use. Keep out of reach of children.